• ROS-Responsive LNPs for Tumor-Selective mRNA

  2026-09-16

  This study reports a combinatorial library of thioketal-containing, ROS-degradable lipid nanoparticles that preferentially release mRNA in tumor cells. The lead lipid, BAmP-TK-12, delivered DUF5-encoding mRNA to deplete mutant RAS and suppress tumor growth, providing a framework for disease-responsive mRNA therapeutics.

• Cy5 TSA Fluorescence System Kit for Astrocyte Mapping

  2026-09-16

  The Cy5 TSA Fluorescence System Kit converts weak HRP activity into a high-density fluorescent signal for spatial validation of astrocyte markers, developmental states, and region-specific transcripts. Its strongest use case is low-abundance target detection in tissue sections where conventional immunofluorescence or FISH lacks sufficient sensitivity.

• Proteoform-Specific Drug Interactions in Native Membranes

  2026-09-15

  Lutomski and colleagues developed a native top-down mass spectrometry workflow that connects membrane-protein post-translational modifications with ligand binding in an intact lipid environment. Using retinal rhodopsin, G proteins, and PDE6, the study shows that proteoform identity can shape drug selectivity and off-target interactions, providing a more precise framework for membrane-targeted drug discovery.

• Dynasore for Endocytosis Research Workflows

  2026-09-15

  Dynasore provides a fast, reversible way to test whether dynamin-dependent membrane scission contributes to cellular uptake, vesicle recycling, or signaling. This workflow translates findings from a human corneal epithelial nanoparticle study into practical assay design, dosing, controls, and troubleshooting.

• Cy5 TSA Fluorescence System Kit for IHC

  2026-09-14

  The Cy5 TSA Fluorescence System Kit converts an HRP signal into a highly localized Cy5 deposit, helping researchers visualize scarce targets in tissue, cells, and hybridization assays. Its strongest use case is sensitive spatial mapping of inflammatory markers such as NLRP3 in atherosclerosis models, while its main optimization challenge is controlling background and deposition time.

• 4-PBA: Turning ER Stress into Translational Insight

  2026-09-14

  4-Phenylbutyric acid is more than an ER stress reagent: it is a mechanistic probe for testing whether proteostasis failure drives apoptosis or autophagic cell death. This article translates recent liver-cancer findings into a rigorous rescue-assay strategy for translational researchers.

• Oltipraz: Nrf2 Activation for Liver Research

  2026-09-13

  Oltipraz is a small-molecule Nrf2 pathway activator and phase II enzyme inducer used in chemoprevention and redox-biology research. The product dossier reports induction activity in rat hepatocyte assays at an approximate IC50 range of 10–30 μM, while MASLD evidence from a separate Qushi Huoxue ointment study should not be interpreted as direct Oltipraz efficacy.

• Exendin-4 Workflows for Beta Cell Research

  2026-09-12

  Build reproducible Exendin-4 assays around cAMP signaling, glucose-induced insulin secretion, and beta cell performance. The workflow also shows how recent yeast-expression research can inform affordable production studies without conflating immunoreactive expression with validated biological activity.

• Azathramycin A: Assay Design for TB Research

  2026-09-11

  Azathramycin A is a macrolide antibiotic and research tool for studying ribosome-directed protein synthesis inhibition in tuberculosis. This article presents a stability-aware assay framework that separates compound identity, exposure, binding, and antibacterial response.

• I-BET151 and the Super-Enhancer–Disulfidptosis Axis

  2026-09-11

  Explore how I-BET151 (GSK1210151A) can serve as a pharmacological probe for linking BET-dependent transcription to the FOXA1–SLC7A11–disulfidptosis axis. This article translates recent prostate cancer findings into rigorous assay and experimental-design decisions.

• Dynasore: From Endocytosis to Translation

  2026-09-10

  Dynasore is more than a pathway blocker: used with cargo-specific assays, viability controls, and engineered uptake models, it can help translational researchers distinguish dynamin-dependent entry from the broader biology of nanoparticle trafficking.

• Anisomycin and JNK: From Apoptosis to Memory

  2026-09-10

  Anisomycin is more than a conventional apoptosis tool: used strategically, it can help translational researchers test how JNK-centered stress signaling intersects with synaptic plasticity and social memory maintenance. This article connects established cancer biology with the neuroligin 1 proteolysis pathway while defining the evidence, controls, and limitations required for responsible cross-domain experimentation.

• Dynasore: Practical Workflow for Endocytosis Assays

  2026-09-09

  Dynasore (SKU A1605) is a cell-permeable dynamin GTPase inhibitor for testing dynamin-dependent membrane fission, uptake, and vesicle-trafficking phenotypes in cell-based assays. It is appropriate as a reversible perturbation tool, but should not be used alone to assign a specific endocytic route, establish therapeutic efficacy, or generalize an IC50 across cell models.

• AZ505: Selective SMYD2 Inhibitor for Research

  2026-09-09

  AZ505 is a substrate-competitive SMYD2 inhibitor that blocks peptide-substrate methylation without directly competing with SAM. Its reported biochemical potency, selectivity profile, and use in cisplatin-induced renal fibrosis models support epigenetic regulation research and cancer biology research.

• Dynasore A1605: Reliable Endocytosis Workflows

  2026-09-08

  This scenario-driven guide explains how Dynasore (SKU A1605) can clarify viability, uptake, and trafficking results when dynamin-dependent endocytosis is part of the experimental model. It combines product-specific handling information with peer-reviewed evidence and practical controls for reproducible cell-based assays.

8517 records 1/568 page Next 12345 下5页 Last page